Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low-grade lymphoma: the optimal timing.

J Gibson1, P J Ho, D Joshua

  • 1Institute of Haematology, Royal Prince Alfred Hospital; Camperdown, Australia. jgibson@haem.rpa.cs.nsw.gov.au

Transplantation Proceedings
|November 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics.

Bone marrow transplantation·2020
Same author

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.

Leukemia·2016
Same author

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.

Leukemia·2016
Same author

Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.

Leukemia·2016
Same author

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.

Leukemia·2015
Same author

The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study.

Leukemia·2015
Same journal

Acute Rejection Mediated by Preformed Anti-HLA-C Antibody in a Kidney Transplant Patient: A Case Report.

Transplantation proceedings·2026
Same journal

Liver Transplantation for Metastatic Neuroendocrine Tumors: A Single-Center Experience in a Brazilian Referral Center.

Transplantation proceedings·2026
Same journal

Analysis of the Cost of Maintaining Effective Donors and Nondonors of Organs and Tissues in Intensive Care Units.

Transplantation proceedings·2026
Same journal

Adolescence and Pediatric Heart Transplantation: Impact of Non-Adherence on Mortality: A Single-Center Experience.

Transplantation proceedings·2026
Same journal

Impact of Family-Based Care on the Outcome of Brain Death and Humanization in the Process of Multiple Organ Donation: Case Report.

Transplantation proceedings·2026
Same journal

Karnofsky Performance Status Is Associated with Patient and Graft Survival After Liver Retransplantation.

Transplantation proceedings·2026
See all related articles

High-dose therapy (HDT) with autologous stem cell support shows promise for follicular lymphoma (FL) patients with poor prognoses. Early transplantation and careful patient selection are key to improving outcomes in this challenging hematologic malignancy.

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Medicine

Background:

  • Follicular lymphoma (FL) is the most common indolent non-Hodgkin's lymphoma, with a median survival of 7-10 years.
  • Patients with poor prognostic features have a median survival under 2 years, and conventional chemotherapy often fails.
  • Relapsing disease and increasing drug resistance are common challenges in FL management.

Purpose of the Study:

  • To evaluate the efficacy of high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) for follicular lymphoma.
  • To identify key factors predicting successful transplantation outcomes in FL patients.
  • To review current evidence and ongoing research regarding HDT and stem cell transplantation in FL.

Main Methods:

  • Review of historical comparisons, registry analyses, and randomized trials of HDT with ASCT in relapsed/refractory FL.

Related Experiment Videos

  • Analysis of studies investigating HDT with ASCT as initial therapy or in first remission.
  • Evaluation of purging strategies for autologous transplants and the role of allogeneic transplantation.

    • Main Results:

    • Historical data and registry analyses suggest support for HDT with ASCT in relapsed/refractory FL.
    • Early transplantation and appropriate patient selection are crucial for successful outcomes.
    • Preliminary analyses of randomized trials indicate a potential advantage for HDT, but longer follow-up is needed.
    • Purging strategies and nonmyeloablative conditioning require further investigation.

    Conclusions:

    • HDT with ASCT is a promising approach for selected FL patients, particularly those with poor prognoses.
    • Further research and longer follow-up are necessary to confirm the benefits of HDT and optimize transplantation strategies.
    • Allogeneic transplantation is limited by complications, and nonmyeloablative strategies need further validation.